Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

Anastasis21 Jun. 4 at 8:09 PM

$IMMX tommorow 9!!!!!

0 · Reply

Anastasis21 Jun. 4 at 8:08 PM

$IMMX

0 · Reply

Niddi Jun. 4 at 6:58 PM

$IMMX Wouldn’t it be nice if SEC makes Shorting illegal

2 · Reply

Niddi Jun. 4 at 5:42 PM

$IMMX Adding

0 · Reply

gbpchillin Jun. 4 at 5:38 PM

$IMMX

0 · Reply

Loaf_of_Brade Jun. 4 at 5:26 PM

$IMMX it’s dead

0 · Reply

Niddi Jun. 4 at 4:58 PM

$IMMX Be patient.

0 · Reply

Anastasis21 Jun. 4 at 4:50 PM

$IMMX another great day we all know where is going!!!!

0 · Reply

Bernic88 Jun. 4 at 9:26 AM

$IMMX There have been some very strange pre-market movements all week long. I think we're about to see a major move here soon—and more likely to the upside than the downside. Quite interesting.

1 · Reply

bnglao24 Jun. 3 at 10:52 PM

$IMMX Are we expected to wait until late Sept, at minimum, to understand the strategic urgency of raising before the market absorbed the latest data drop? Stated Ph3 frontline trial timelines don’t justify the urgency…..so what’s up? 🤨

3 · Reply

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

2026-05-22T14:41:00.000Z - 13 days ago

Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright

May 21, 2026, 6:30 AM EDT - 14 days ago

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

2026-05-21T10:10:33.000Z - 14 days ago

Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis

$Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2$

May 21, 2026, 6:00 AM EDT - 14 days ago

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Immix Biopharma Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 5 weeks ago

Immix Biopharma Slides: Corporate presentation

Apr 9, 2026, 8:45 AM EDT - 2 months ago

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Immix Biopharma Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Immix Biopharma Proxy statement: Proxy filing

2026-03-30T13:38:42.000Z - 2 months ago

Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon

MRK

$Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones$

Mar 30, 2026, 8:45 AM EDT - 2 months ago

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

2026-03-30T11:30:46.000Z - 2 months ago

Immix Biopharma price target raised to $15 from $14 at Mizuho

2026-03-27T10:16:27.000Z - 2 months ago

Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright

Mar 25, 2026, 7:00 AM EDT - 2 months ago

Immix Biopharma Annual report: Q4 2025

2026-03-25T08:55:10.000Z - 2 months ago

Immix Biopharma initiated with an Overweight at Morgan Stanley

2026-03-09T08:50:20.000Z - 3 months ago

Immix Biopharma initiated with an Outperform at Citizens

Mar 4, 2026, 6:00 AM EST - 3 months ago

Immix Biopharma Slides: Corporate presentation

Mar 3, 2026, 8:45 AM EST - 3 months ago

Immix Biopharma to Participate in Upcoming Investor Conferences

2026-02-09T10:40:13.000Z - 4 months ago

Immix Biopharma initiated with an Outperform at Mizuho

2026-01-28T13:50:28.000Z - 4 months ago

Immix Biopharma receives FDA breakthrough therapy designation for NXC-201

Jan 28, 2026, 8:45 AM EST - 4 months ago

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

2026-01-09T22:30:15.000Z - 5 months ago

Immix Biopharma files $750M mixed securities shelf

Jan 9, 2026, 7:00 AM EST - 5 months ago

Immix Biopharma Registration statement: Registration Filing

Dec 9, 2025, 5:45 PM EST - 6 months ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2025-12-09T13:30:52.000Z - 6 months ago

Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright

2025-12-08T11:25:27.000Z - 6 months ago

Immix Biopharma 19.12M share Spot Secondary priced at $5.10

2025-12-08T01:50:12.000Z - 6 months ago

Immix Biopharma announces phase 2 NXC-201 results

Dec 7, 2025, 6:20 PM EST - 6 months ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

$At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Dec 7, 2025, 6:15 PM EST - 6 months ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

2025-11-12T13:50:43.000Z - 7 months ago

Immix Biopharma appoints Grabow as Chief Commercial Officer

Nov 12, 2025, 8:45 AM EST - 7 months ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 7, 2025, 4:00 PM EST - 7 months ago

Immix Biopharma Quarterly report: Q3 2025

Nov 3, 2025, 8:45 AM EST - 7 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Oct 14, 2025, 8:45 AM EDT - 8 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 6, 2025, 4:05 PM EDT - 8 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

2025-10-06T12:15:52.000Z - 8 months ago

Immix Biopharma files to sell 6.85M shares of common stock for holders

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Immix Biopharma Registration statement: Registration Filing

Oct 1, 2025, 8:45 AM EDT - 8 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

$Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2$

Sep 18, 2025, 1:30 PM EDT - 9 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

2025-09-12T10:15:17.000Z - 9 months ago

Immix Biopharma price target raised to $8 from $7 at H.C. Wainwright

2025-09-11T13:35:30.000Z - 9 months ago

Immix Biopharma appoints Nancy Chang to board of directors

Sep 11, 2025, 9:15 AM EDT - 9 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

2025-09-08T20:20:08.000Z - 9 months ago

Immix Biopharma receives strategic investment from Goose Capital

Sep 8, 2025, 4:05 PM EDT - 9 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Aug 25, 2025, 9:30 AM EDT - 10 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 8, 2025, 7:00 AM EDT - 10 months ago

Immix Biopharma Quarterly report: Q2 2025

Aug 6, 2025, 12:30 PM EDT - 10 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

2025-07-11T13:40:51.000Z - 11 months ago

Immix Biopharma announces ‘class-leading’ safety profile for NXC-201

Jul 11, 2025, 9:36 AM EDT - 11 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 11 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Immix Biopharma Slides: Corporate Presentation

Jun 6, 2025, 9:39 AM EDT - 1 year ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

Jun 3, 2025, 3:00 PM EDT - 1 year ago

Immix Biopharma Transcript: Status Update

Jun 3, 2025, 3:00 PM EDT - 1 year ago

Immix Biopharma Press release: Status Update

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 1 year ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 1 year ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 1 year ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 1 year ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 19, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Proxy statement: Proxy Filing

May 7, 2025, 6:00 PM EDT - 1 year ago

Immix Biopharma Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Proxy statement: Proxy Filing

Apr 23, 2025, 10:04 AM EDT - 1 year ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Immix Biopharma Annual report: Q4 2024

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 1 year ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 20, 2025, 6:00 PM EST - 1 year ago

Immix Biopharma Slides: Investor Presentation

Jan 7, 2025, 9:34 AM EST - 1 year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 1 year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Nov 11, 2024, 6:00 PM EST - 1 year ago

Immix Biopharma Quarterly report: Q3 2024

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Aug 11, 2024, 6:00 PM EDT - 1 year ago

Immix Biopharma Quarterly report: Q2 2024

Jul 25, 2024, 9:36 PM EDT - 2 years ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 2 years ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

May 21, 2024, 8:00 AM EDT - 2 years ago

Immix Biopharma Proxy statement: Proxy Filing

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

May 8, 2024, 6:00 PM EDT - 2 years ago

Immix Biopharma Quarterly report: Q1 2024

Apr 29, 2024, 9:39 AM EDT - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immix Biopharma Proxy statement: Proxy Filing

Apr 18, 2024, 9:32 AM EDT - 2 years ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 2 years ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 28, 2024, 7:00 PM EDT - 2 years ago

Immix Biopharma Annual report: Q4 2023

Mar 20, 2024, 9:46 AM EDT - 2 years ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Anastasis21 Jun. 4 at 8:09 PM

$IMMX tommorow 9!!!!!

0 · Reply

Anastasis21 Jun. 4 at 8:08 PM

$IMMX

0 · Reply

Niddi Jun. 4 at 6:58 PM

$IMMX Wouldn’t it be nice if SEC makes Shorting illegal

2 · Reply

Niddi Jun. 4 at 5:42 PM

$IMMX Adding

0 · Reply

gbpchillin Jun. 4 at 5:38 PM

$IMMX

0 · Reply

Loaf_of_Brade Jun. 4 at 5:26 PM

$IMMX it’s dead

0 · Reply

Niddi Jun. 4 at 4:58 PM

$IMMX Be patient.

0 · Reply

Anastasis21 Jun. 4 at 4:50 PM

$IMMX another great day we all know where is going!!!!

0 · Reply

Bernic88 Jun. 4 at 9:26 AM

$IMMX There have been some very strange pre-market movements all week long. I think we're about to see a major move here soon—and more likely to the upside than the downside. Quite interesting.

1 · Reply

bnglao24 Jun. 3 at 10:52 PM

3 · Reply

Anastasis21 Jun. 3 at 8:02 PM

$IMMX another bullshit day

0 · Reply

Dingalingading Jun. 3 at 7:58 PM

$IMMX f off shorts

0 · Reply

StockSniperD Jun. 3 at 2:23 PM

$IMMX The squeeze is coming

0 · Reply

Anastasis21 Jun. 3 at 1:48 PM

$IMMX i am affaid that another ugly day is here

0 · Reply

CrossCountryStocks Jun. 3 at 12:47 PM

$IMMX come baby here we go, or are you going to make me buy more

0 · Reply

Bernic88 Jun. 3 at 10:20 AM

$IMMX 👀🤫

0 · Reply

Bernic88 Jun. 3 at 3:22 AM

$IMMX $8.20 must hold; otherwise, we could see prices in the low $7S again.

1 · Reply

Martylevitt Jun. 2 at 10:50 PM

$IMMX Short it and forget it.

2 · Reply

Niddi Jun. 2 at 7:25 PM

$IMMX Good time to add imho.

2 · Reply

Bernic88 Jun. 2 at 5:51 PM

$IMMX If you know what you hold, days like these don't matter in the long run. So enjoy the ride.

0 · Reply

HornyUnicorn Jun. 2 at 5:31 PM

$IMMX Check out today, almost all bio titles are red. Probably the worst day so far this year

0 · Reply

Ivorthedriver Jun. 2 at 4:26 PM

$IMMX Could it be the inside manipulation that precedes new info released at Jefferies? I hope so... Also, I put a bid in for some June $10 calls...let's see if I get a bite! Ivor

3 · Reply

Market Cap	459.23M
Revenue (ttm)	0.00
Net Income (ttm)	-29.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,224,000
Avg Vol	1,003,408
Day's Range	N/A - N/A
Shares Out	54.41M
Stochastic %K	12%
Beta	0.10
Analysts	Strong Sell
Price Target	$19.50